Nortriptyline
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Nortriptyline: From Depression to Attention Deficit-Hyperactivity Disorder (ADHD)
One-Sentence Summary
Nortriptyline is a tricyclic antidepressant (TCA) with established efficacy in major depressive disorder, evidenced within this evidence pack by multiple head-to-head trials against SSRIs. The TxGNN model predicts it may also be effective for Attention Deficit-Hyperactivity Disorder (ADHD), with 20 supporting publications but no ADHD-specific clinical trials currently registered.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Depression (Major Depressive Disorder) |
| Predicted New Indication | Attention Deficit-Hyperactivity Disorder (ADHD) |
| TxGNN Prediction Score | 99.42% |
| Evidence Level | L3 |
| Australia Market Status | Not Marketed |
| Number of ARTG Entries | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not available in this evidence pack (flagged as a High-severity data gap). Based on known pharmacology, nortriptyline is a tricyclic antidepressant that acts primarily as a norepinephrine reuptake inhibitor (with weaker serotonergic activity), and its efficacy in major depressive disorder is well established — reflected in this evidence pack by numerous comparative trials against sertraline, escitalopram and fluvoxamine.
The predicted new indication, ADHD, has mechanistic plausibility: ADHD’s prefrontal-cortex noradrenergic dysregulation hypothesis overlaps with nortriptyline’s norepinephrine reuptake inhibition. Nortriptyline is recognised in the literature as one of the more noradrenergic-selective TCAs historically used as a second-line, non-stimulant ADHD treatment, particularly in patients with comorbid tic disorder or Tourette syndrome, where stimulants risk exacerbating tics.
This mechanism is considered plausible but non-primary, since it is indirect relative to first-line ADHD agents (stimulants, atomoxetine), and nortriptyline’s narrow therapeutic index and cardiovascular toxicity risk have limited its contemporary use in this population.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 11052409 | 2000 | RCT (small controlled study) | J Child Adolesc Psychopharmacol | Controlled study of nortriptyline’s efficacy and tolerability in paediatric ADHD |
| 22700161 | 2012 | RCT | Pediatric Nephrology | Randomised double-blind controlled trial of nortriptyline for enuresis in children with ADHD |
| 8428873 | 1993 | Controlled study (comorbid subgroup) | J Am Acad Child Adolesc Psychiatry | Nortriptyline treatment in children with ADHD and comorbid tic disorder/Tourette’s syndrome |
| 25238582 | 2014 | Review (Cochrane) | Cochrane Database Syst Rev | Systematic review of tricyclic antidepressants, including nortriptyline, for ADHD in children/adolescents |
| 7807071 | 1995 | Systematic assessment | J Nerv Ment Dis | Systematic assessment of TCAs, including nortriptyline, in adult ADHD |
| 15064003 | 2004 | Review | Psychiatr Clin North Am | Reviews nortriptyline among noradrenergic secondary-amine TCAs as a nonstimulant ADHD option |
| 9629412 | 1997 | Review | Arq Neuropsiquiatr | Review of stimulant and antidepressant (including nortriptyline) use in ADHD |
| 12270803 | 2002 | Review | Adolesc Med | Overview of ADHD psychopharmacology including tricyclic antidepressants (nortriptyline, imipramine, desipramine) |
| 4075308 | 1985 | Open-label/case series | Clin Neuropharmacol | Early case series of nortriptyline use in attention deficit disorder |
| 8444754 | 1993 | Retrospective study | J Am Acad Child Adolesc Psychiatry | Retrospective review of serum levels and ECG effects of nortriptyline in children/adolescents — safety-relevant |
Safety Considerations
Please refer to the TGA-approved Product Information (PI) for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence is limited to one small controlled paediatric trial, one RCT for a secondary outcome (enuresis), a Cochrane review, and several older case series/retrospective analyses (Evidence Level L3) — with no ADHD-specific clinical trials currently registered. Nortriptyline is also not currently marketed in Australia (0 ARTG entries), and a Blocking-severity data gap on TFDA/TGA product safety information means a formal safety review (S1) cannot yet proceed.
To proceed, the following is needed:
- TGA-approved Product Information (PI): warnings, contraindications, and drug interaction data
- Mechanism of action (MOA) documentation (e.g. via DrugBank)
- Confirmation of an Australian market/import pathway (currently no ARTG entries)
- A dedicated, adequately powered ADHD clinical trial to move beyond exploratory (Research Question) status
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.